<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02562807</url>
  </required_header>
  <id_info>
    <org_study_id>10060040</org_study_id>
    <nct_id>NCT02562807</nct_id>
  </id_info>
  <brief_title>A Study of TAS-303 in Female Patients With Stress Urinary Incontinence</brief_title>
  <official_title>A Phase I Study of TAS-303 in Female Patients With Stress Urinary Incontinence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taiho Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taiho Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate pharmacological effect, safety and pharmacokinetic
      of TAS-303 in female patients with Stress Urinary Incontinence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is double-blind, placebo-controlled crossover study. The main purpose of this
      study is to evaluate Urethral Pressure Profile Parameters in Stress Urinary Incontinence
      patients who will receive single dose of TAS-303 or Placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Maximum Urethral Closure Pressure (MUCP)</measure>
    <time_frame>Baseline, 6 hours after the administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urethral pressure profile parameters: mean urethral closure pressure, functional profile length</measure>
    <time_frame>Baseline, 6 hours after the administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by incidence and severity of adverse events</measure>
    <time_frame>Up to 36 days after the administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) of TAS-303</measure>
    <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72 hours after the administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration (tmax) of TAS-303</measure>
    <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72 hours after the administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of TAS-303</measure>
    <time_frame>Immediately prior to dosing, and 1, 2, 4, 6, 8, 12, 24, 48, 72 hours after the administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-time (t1/2) of TAS-303</measure>
    <time_frame>1, 2, 4, 6, 8, 12, 24, 48, 72 hours after the administration</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Stress Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TAS-303 18mg single-dose and then Placebo single-dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo single-dose and then TAS-303 18mg single-dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TAS-303 9mg single-dose and then Placebo single-dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>TAS-303 Placebo single-dose and then TAS-303 9mg single-dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAS-303 18mg single-dose</intervention_name>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 18mg single-dose</intervention_name>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAS-303 9mg single-dose</intervention_name>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_label>Treatment D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 9mg single-dose</intervention_name>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_label>Treatment D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Patient has symptoms of Stress Urinary Incontinence (SUI) for at least 12 weeks prior
             to study entry

          -  Patient weights at least 45 kg and has body mass index (BMI) range of 18.0-30.0 kg/m2,
             inclusive, at screening

          -  Patient is positive in 1-hour pad weight test at screening

          -  Patient has at least 2 incontinence episodes per week.

        Key Exclusion Criteria:

          -  Patient has predominant or primary urge incontinence according to investigator
             judgment

          -  Patient had a prior surgical SUI treatment

          -  Patient is diagnosed Pelvic Organ Prolapse

          -  Patient is currently taking medication, or has taken medication in the last 4 weeks,
             for urinary incontinence or that effect urinary output function including
             anti-cholinergic or anti-histamines or any anti-anxiety medications.

          -  Patient is positive pregnancy test
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Taiho Pharmaceutical Co., Ltd.</last_name>
    <role>Study Director</role>
    <affiliation>Taiho Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Taiho Pharmaceutical Co., Ltd selected site</name>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2015</study_first_submitted>
  <study_first_submitted_qc>September 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2015</study_first_posted>
  <last_update_submitted>August 9, 2016</last_update_submitted>
  <last_update_submitted_qc>August 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Urinary Incontinence</keyword>
  <keyword>Urinary Incontinence, Stress</keyword>
  <keyword>Lower Urinary Tract Symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

